Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease

Publication date: September 2019Source: Revista Española de Cardiología (English Edition), Volume 72, Issue 9Author(s): Vanesa Viana-Huete, José J. FusterAbstractClinical trials have unequivocally shown that cholesterol-lowering drugs decrease the risk of atherosclerotic cardiovascular disease in an exceptionally wide range of individuals. Yet, even when treated optimally according to current standards, many individuals still experience life-threatening ischemic events. Emerging experimental and clinical evidence strongly suggests that persistent inflammation is a major driver of this residual risk, which has opened the door to the application of anti-inflammatory drugs for cardiovascular disease prevention. Here, we review our current knowledge of the biology of interleukin-1β, a key regulator of inflammation in atherosclerotic plaque and the target of the first clinical trial to demonstrate that an anti-inflammatory drug can effectively reduce cardiovascular risk. We discuss the challenges faced by interleukin-1β inhibitors and other anti-inflammatory compounds in their translation to the clinical scenario, and identify other potential targets within this signaling pathway that hold promise in the cardiovascular setting.ResumenMúltiples ensayos clínicos han demostrado de forma inequívoca que los medicamentos hipocolesterolemiantes disminuyen el riesgo de enfermedad cardiovascular ateroesclerótica de una muy amplia variedad de personas. A pesar de esto, muchas perso...
Source: Revista Espanola de Cardiologia - Category: Cardiology Source Type: research